Press Releases
-
Parallel programs will advance MIIST305 in ulcerative colitis (UC) and gastrointestinal acute radiation syndrome (GI-ARS) Phase 1 clinical studies expected to begin in 2025 CLAREMONT, Calif., April 25, 2024 – […] More
-
ALPHARETTA, GA, October 19, 2021 – Scapa Healthcare, an SWM International (NYSE: SWM) business and the trusted strategic partner for the world’s leading companies in advanced wound care, consumer wellness, […] More
-
– Trial funded by Defense Health Agency (DHA) through US Army Medical Research and Development Command’s (USAMRDC) Small Business Innovation Research (SBIR) program – – SynePure and Catasyn are FDA […] More
-
02/18/2021 | Synedgen Appoints Industry Veteran Dennis Fenton, Ph.D., to Board of Directors
CLAREMONT, Calif. February 18, 2021 – Synedgen, a biopharma company dedicated to using its Multivalent Innate Immune Signaling Target (MIIST) platform to develop drugs that mimic and enhance the innate […] More
-
– Grant will fund understanding of the biochemical and biophysical structure of the endothelial glycocalyx – – Synedgen’s CEO, Shenda Baker, gave a related keynote lecture at the Pan Pacific […] More
-
– Additional funding increases cumulative NEI commitment to over $1 million – – All selected molecules synthesized under this initiative have met prerequisite development criteria – CLAREMONT, Calif. October […] More
-
06/04/2020 | Synedgen Receives FDA 510(k) Clearance for Synvaza™ Mouth Sore and Wound Rinse
– Synvaza is an oral treatment that manages pain and promotes healing for many types of oral wounds, injuries, and ulcers – – Premium addition to Prisyna, Synedgen’s oral health […] More
-
– Funds commercialization and head-to-head clinical trial against current standard of care – – Also announces abstract at 9th RAND Corporation and Department of Defense State-of-the-Science Meeting on Blast-Related Burn […] More
-
– First results from ocular injury program to treat damage from sulfur mustard gas – – Announces $1 million funding from the National Eye Institute for continuation of program development […] More
-
01/29/2020 | Synedgen Receives $2.6 Million in Private Financing For Wound Care Portfolio
– Investment funds commercialization efforts for FDA 510(k)-cleared products Catasyn and SynePure – CLAREMONT, Calif. January 29, 2020 – Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance […] More
-
01/15/2020 | Synedgen Granted New EU Patent For Treating GI Mucositis
– Patent adds to company’s robust portfolio covering lead development candidate SYGN305 – CLAREMONT, Calif. January 15, 2020 – Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance […] More
-
12/13/2019 | Synedgen Awarded Funding to Advance Inflammatory Bowel Disease Treatments
– Glycopolymers aimed at reducing inflammation and damage associated with ulcerations of the lower bowel – CLAREMONT, Calif. December 13, 2019 – Synedgen, a biotechnology company using glycochemistry to develop […] More
-
10/10/2018 | Synedgen Announces the Launch of Moisyn Rinse to Treat Dry Mouth
CLAREMONT, Calif. – October 10, 2018 – Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the market launch […] More
-
09/19/2018 | Synedgen Appoints Kaveri Parker, Ph.D. as Chief Business Officer
CLAREMONT, Calif.- September 19, 2018 – Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the appointment of Kaveri […] More
-
— Synvaza reduces pain associated with erosive or ulcerative oral lesions — CLAREMONT, Calif. – July 11, 2018 – Prisyna, the oral care division of Synedgen, founded to optimize oral […] More
-
05/23/2018 | Synedgen Receives FDA 510(k) Clearance for Catasyn™ Advanced Technology Wound Hydrogel
May 23, 2018–Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced that it has received 510(k) clearance from the […] More
-
05/09/2018 | Prisyna Receives FDA 510(k) Clearance for Moisyn Product Line to Treat Dry Mouth
— Company’s innovative glycomics technology now addresses large population suffering from xerostomia — CLAREMONT, Calif. – May 9, 2018– Prisyna, the oral care division of Synedgen, founded to optimize oral […] More
-
04/17/2018 | Prisyna Appoints Leo Pranitis as General Manager
— Experienced healthcare executive to build oral health franchise and expand Prisyna brand — CLAREMONT, Calif. – April 17, 2018 – Prisyna, the oral care division of Synedgen, founded to […] More
-
February 15, 2018–Synedgen announces the appointment of Allister J. Loughran, PhD as Senior Scientist to lead its research operations and to expand research indications for its platform of biologically active […] More
-
— New understanding of role of ions could impact treatment of infectious and inflammatory diseases — CLAREMONT, Calif.-January 31, 2018–Synedgen, a company leveraging its proprietary glycomics technology platform to develop […] More
-
10/30/2017 | Prisyna announces new Synedent FLX Mouthwash With Fluoride
New Product, New Look, New Larger Bottles October 31, 2017 Claremont CA—Prisyna today announces the upcoming launch of its latest product, Synedent FLX®. Synedent FLX was developed in response to […] More
-
CLAREMONT, Calif. – October 27, 2016 – Synedgen, a company leveraging a unique proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory disorders associated with the lung, […] More
-
Preclinical Data to be Presented at North American Cystic Fibrosis Conference More
-
04/28/2016 | Prisyna Secures $6M in Financing
Top-line data on Moistagen for dry mouth demonstrates statistically significant outcomes. Funding to support completion of clinical studies of multiple products, FDA device market clearance process and marketing efforts in […] More
-
03/05/2016 | Prisyna Helps Dry Mouth Patients Get Moist Again
Prisyna Announces Oral Clinical Study Results March 5, 2016 Claremont CA—Prisyna today announces the first results from a 57 patient clinical study evaluating Moisyn Oral Rinse to help alleviate the […] More
-
Innovative Treatments to Improve GI & Lung Health and Antibiotic Effectiveness in CF Patients More
-
08/24/2015 | Synedgen Receives FDA Clearance for its SynePure Wound Cleanser
CLAREMONT, Calif. — August 24, 2015– Synedgen announces U.S. Food and Drug Administration 510(k) clearance to market its SynePureTM Wound Cleanser (K143444). SynePure Wound Cleanser is intended for the cleansing […] More
-
12/15/2014 | Synedgen Welcomes New Board Member Paul Grint
Recognized Industry Leader in Pharmaceutical Development More
-
Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel More
-
05/30/2014 | Planning for Human Clinical Trials
Synedgen Appoints Toxicology Specialists More